Pharmacokinetics of the etonogestrel contraceptive implant in obese women
- PMID: 22717269
- DOI: 10.1016/j.ajog.2012.05.002
Pharmacokinetics of the etonogestrel contraceptive implant in obese women
Abstract
Objective: We sought to examine the pharmacokinetics and acceptability of the etonogestrel contraceptive implant in obese women.
Study design: We developed and validated a plasma etonogestrel concentration assay and enrolled 13 obese (body mass index ≥30) women and 4 normal-weight (body mass index <25) women, who ensured comparability with historical controls. Etonogestrel concentrations were measured at 50-hour intervals through 300 hours postinsertion, then at 3 and 6 months to establish a pharmacokinetic curve.
Results: All obese participants were African American, while all normal-weight participants were white. Across time, the plasma etonogestrel concentrations in obese women were lower than published values for normal-weight women and 31-63% lower than in the normal-weight study cohort, although these differences were not statistically significant. The implant device was found highly acceptable among obese women.
Conclusion: Obese women have lower plasma etonogestrel concentration than normal-weight women in the first 6 months after implant insertion. These findings should not be interpreted as decreased contraceptive effectiveness without additional considerations.
Copyright © 2012 Mosby, Inc. All rights reserved.
Similar articles
-
Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.Contraception. 2019 Jul;100(1):37-41. doi: 10.1016/j.contraception.2019.03.045. Epub 2019 Apr 10. Contraception. 2019. PMID: 30980827 Free PMC article.
-
Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.Contraception. 2020 Dec;102(6):403-405. doi: 10.1016/j.contraception.2020.08.011. Epub 2020 Aug 26. Contraception. 2020. PMID: 32858051 Free PMC article.
-
Plasma concentrations of etonogestrel in women using oral desogestrel before and after Roux-en-Y gastric bypass surgery: a pharmacokinetic study.BJOG. 2019 Mar;126(4):486-492. doi: 10.1111/1471-0528.15511. Epub 2018 Nov 16. BJOG. 2019. PMID: 30347490 Clinical Trial.
-
The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.Eur J Contracept Reprod Health Care. 2000 Sep;5 Suppl 2:12-20. Eur J Contracept Reprod Health Care. 2000. PMID: 11246602 Review.
-
Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. Cochrane Database Syst Rev. 2016. PMID: 27537097 Free PMC article. Review.
Cited by
-
Obesity and hormonal contraceptive efficacy.Womens Health (Lond). 2013 Sep;9(5):453-66. doi: 10.2217/whe.13.41. Womens Health (Lond). 2013. PMID: 24007251 Free PMC article. Review.
-
A Review of the Toxicologic Implications of Obesity.J Med Toxicol. 2015 Sep;11(3):342-54. doi: 10.1007/s13181-015-0488-6. J Med Toxicol. 2015. PMID: 26108709 Free PMC article. Review.
-
Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review.Curr Obstet Gynecol Rep. 2020 Jun;9(2):72-78. doi: 10.1007/s13669-020-00284-y. Epub 2020 May 4. Curr Obstet Gynecol Rep. 2020. PMID: 33117601 Free PMC article.
-
Long-acting reversible contraception with etonogestrel implants in female macaques (Macaca mulatta and Macaca fascicularis).Front Vet Sci. 2024 Jan 8;10:1319862. doi: 10.3389/fvets.2023.1319862. eCollection 2023. Front Vet Sci. 2024. PMID: 38260208 Free PMC article.
-
Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.Contraception. 2019 Jul;100(1):37-41. doi: 10.1016/j.contraception.2019.03.045. Epub 2019 Apr 10. Contraception. 2019. PMID: 30980827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
